

This notice (the "Notice") is sent to you as Shareholder of the Fund. It is important and requires your immediate attention. If you are in any doubt as to the action to be taken, you are advised to consult your stockbroker, solicitor or attorney, accountant or other independent financial adviser. If you have sold or otherwise transferred your holding in the Fund, please send at once this document to the stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. Where appropriate, please pass the contents of this communication on to the beneficial investors of the Fund.

This Notice has not been reviewed by the Central Bank of Ireland (the "**Central Bank**"), and it is possible that changes thereto may be necessary to meet the Central Bank's requirements. The Directors are of the opinion that there is nothing contained in this Notice or in the proposals detailed herein that conflicts with the CBI UCITS Regulations, the guidance issued by, and the regulations of, the Central Bank. The Directors accept responsibility for the information contained in this Notice.

Capitalised terms used in this notice shall have the same meaning ascribed to them in the latest version of the Prospectus unless the context otherwise requires.

LETTER FROM THE BOARD
TO THE SHAREHOLDER OF
VANECK – EMERGING MARKETS EQUITY UCITS (the "Fund")

REGISTERED OFFICE

33 Sir John Rogerson's Quay
Dublin 2
D02 XK09
Ireland

VanEck ICAV
(an umbrella fund with segregated liability between sub-funds)
33 Sir John Rogerson's Quay
Dublin 2
Ireland

14 November 2025

Dear Shareholder,

This letter is to inform you, on behalf of the board of directors (the “**Directors**”) of the VanEck ICAV (the “**ICAV**”), of recent developments in respect of the Fund.

After careful consideration with the long-term interests of Shareholders and with the level of assets under management of the Fund in mind, and following consultation with VanEck Asset Management B.V., the Directors have resolved in accordance with Clause 11.1 of Schedule 1 of the instrument of incorporation of the ICAV that it is in the best interest of the Fund and its Shareholders, as a whole, to terminate the Fund with effect from 18 December 2025, or such later day as the Directors may determine and notify to Shareholders in advance (the “**Termination Date**”). The Directors have determined that the ICAV will no longer accept subscriptions into the Fund from the date of this Notice. The termination of the Fund will be affected in accordance with Clause 11.1 of the instrument of incorporation of the ICAV and the Prospectus.

Prior to the Termination Date, Shareholders may submit a redemption request to redeem their holdings in the Fund in accordance with the terms and conditions of the Supplement. Shareholders are also entitled to request a conversion of their Shares in the Fund to Shares in another sub-fund of the ICAV, in accordance with the provisions set out in the section titled “Exchange of Shares” in the Prospectus. If you would like further information, please contact VanEck using the details set out at the end of this Notice. Investors should seek their own advice as to the suitability of any alternative investment option.

Should you remain in the Fund until the Termination Date, you will be redeemed at the redemption price on the Termination Date and will receive, subject to compliance with all anti-money laundering documentation requirements, pro rata to the number of shares held by you in net cash proceeds derived from the realisation of the investments of the Fund and any cash then forming part of the Fund, so far as the same are available for the purpose of such distribution. Following the redemption of all Shares in the Fund, the Directors will in due course apply to the Central Bank for the withdrawal of approval of the Fund as a sub-fund of the ICAV.

Please note that as part of the closure process and before the Termination Date, the ability to meet the investment objective of the Fund may be compromised in the event of significant redemptions and/or as the underlying portfolio of the Fund is liquidated in preparation for its closure.

The fees, costs or expenses incurred in respect of closing the Fund will be paid by VanEck Asset Management B.V. Shareholders should note that the Fund's normal operating costs and transaction costs will continue to be borne by the Fund, and its respective Shareholders, in accordance with the terms of the Supplement until the Termination Date.

Investors are advised to consult their own professional advisers as to the tax implications of the closure of the Fund under the laws of the countries of their nationality, residence, domicile or incorporation.

If you have any queries, concerning the matters outlined in this Notice, please contact your local agent, or (if none) VanEck at the registered address provided above or at international@vaneck.com.

Yours faithfully,

VanEck ICAV

Registered in Dublin as an open-ended variable capital umbrella ICAV with limited liability between sub-funds.

Registration Number C158225. Registered Office as above.

Directors: Mary Canning, Adrian Waters, Gregory Krenzer (USA), Jonathan Simon (USA), Adam Phillips (USA), Jon Lukomnik (USA)
and Gijbert Koning (Netherlands)